Bristol-Myers Squibb Co (XSWX:BMY) E10: CHF1.31 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
78 GF Score
Price CHF50.31
GF Value CHF45.07
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co E10?

Bristol-Myers Squibb Co XSWX:BMY +1.42% 78 E10 is CHF1.31 as of Mar. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 78/100 and a GF Value™ of CHF45.07. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Bristol-Myers Squibb Co's adjusted earnings per share data for the three months ended in Mar. 2026 was CHF1.031. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is CHF1.31 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bristol-Myers Squibb Co's average E10 Growth Rate was 19.40% per year. During the past 3 years, the average E10 Growth Rate was -1.20% per year. During the past 5 years, the average E10 Growth Rate was 3.20% per year. During the past 10 years, the average E10 Growth Rate was -3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Bristol-Myers Squibb Co was 14.10% per year. The lowest was -16.40% per year. And the median was 1.90% per year.

As of today (2026-07-24), Bristol-Myers Squibb Co's current stock price is CHF50.31. Bristol-Myers Squibb Co's E10 for the quarter that ended in Mar. 2026 was CHF1.31. Bristol-Myers Squibb Co's Shiller PE Ratio of today is 38.40.

During the past 13 years, the highest Shiller PE Ratio of Bristol-Myers Squibb Co was 54.46. The lowest was 18.28. And the median was 33.60.


Bristol-Myers Squibb Co  (XSWX:BMY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Bristol-Myers Squibb Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=50.31/1.31
=38.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Bristol-Myers Squibb Co was 54.46. The lowest was 18.28. And the median was 33.60.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Bristol-Myers Squibb Co E10 Related Terms


Bristol-Myers Squibb Co E10 Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co E10 Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.31

XSWX:BMY vs PFE, GILD, AMGN: E10 Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Shiller PE Ratio falls into.


XSWX:BMY
78GF Score
Bristol-Myers Squibb Co XSWX:BMY
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bristol-Myers Squibb Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.031/330.2130*330.2130
=1.031

Current CPI (Mar. 2026) = 330.2130.

Bristol-Myers Squibb Co Quarterly Data

per share eps CPI Adj_EPS
201606 0.669 241.018 0.917
201609 0.701 241.428 0.959
201612 0.540 241.432 0.739
201703 0.941 243.801 1.275
201706 0.542 244.955 0.731
201709 0.491 246.819 0.657
201712 -1.392 246.524 -1.865
201803 0.863 249.554 1.142
201806 0.228 251.989 0.299
201809 1.123 252.439 1.469
201812 0.724 251.233 0.952
201903 1.041 254.202 1.352
201906 0.860 256.143 1.109
201909 0.822 256.759 1.057
201912 -0.540 256.974 -0.694
202003 -0.326 258.115 -0.417
202006 -0.038 257.797 -0.049
202009 0.750 260.280 0.952
202012 -3.953 260.474 -5.011
202103 0.828 264.877 1.032
202106 0.427 271.696 0.519
202109 0.637 274.310 0.767
202112 0.985 278.802 1.167
202203 0.548 287.504 0.629
202206 0.640 296.311 0.713
202209 0.730 296.808 0.812
202212 0.885 296.797 0.985
202303 0.990 301.836 1.083
202306 0.891 305.109 0.964
202309 0.837 307.789 0.898
202312 0.752 306.746 0.810
202403 -5.234 312.332 -5.534
202406 0.742 314.175 0.780
202409 0.508 315.301 0.532
202412 0.036 315.605 0.038
202503 1.060 319.799 1.095
202506 0.520 322.561 0.532
202509 0.860 324.800 0.874
202512 0.422 324.054 0.430
202603 1.031 330.213 1.031

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of CHF1.31 mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a E10 of CHF1.31 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's E10 too high?
Bristol-Myers Squibb Co's current E10 is CHF1.31. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's E10 compare to PFE and GILD?
Bristol-Myers Squibb Co's E10 of CHF1.31 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current E10 is CHF1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current E10 of CHF1.31. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current E10 is CHF1.31. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current E10 is CHF1.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.

Key valuation signals for XSWX:BMY:

  • E10: CHF1.31
  • GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score

Get the complete analysis for XSWX:BMY

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF50.31
Price
CHF45.07
GF Value